RxDoctor Payments Data

Ahmad Daher, MD

Neurology · Chicago, ILNPI 1285925016

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Globus Medical at 42.7% of the total. Reporting peaked in 2023 at $154 and has fallen 80.6% since, to $30 in 2025. That places this record below the midpoint for neurology clinicians in IL, where the typical reported total is $547.

$361in general payments, 2019–2025

Across 6 payments — averaging $60.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$154
  • Novocure Inc.$102
  • Beigene USA, Inc.$30
  • Monteris Medical Corporation$29
  • Mayne Pharma Commercial LLC$24
  • Abbott$20
$326,409in research payments, 2019–2025

Across 35 payments — averaging $9325.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novocure GmbH$290K
  • Incyte Corporation$36K

What the payments were for

  • Food & beverage$361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$361 in reported general payments places this provider in the 45th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$27,538
Medicare patients
103
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levetiracetam19$950
Pregabalin12$790

Paid to pharmacies, not to this prescriber.

Other neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →